(Q35863404)

10 August 2017

1 reference

title

Psychosis in Parkinson's disease. (English)

1 reference

10 August 2017

1 reference

1 reference

2

Michael S Okun

1 reference

10 August 2017

3

Hubert H Fernandez

1 reference

10 August 2017

Dylan P Wint

1

1 reference

10 August 2017

publication date

1 September 2004

1 reference

Journal of Geriatric Psychiatry and Neurology

10 August 2017

published in

1 reference

10 August 2017

volume

17

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

127-136

1 reference

Visual hallucinations associated with Parkinson disease.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Psychosis and Other Psychiatric Manifestations of Levodopa Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Auditory hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Risk factors for nursing home placement in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Prospective longitudinal assessment of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Early dopaminergic drug-induced hallucinations in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Dream phenomena induced by chronic levodopa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Dopaminergic sensitization: implications for the pathogenesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Relapse of paranoid psychotic state in methamphetamine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Prospective study of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

A study of visual hallucinations in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Serotonin and Hallucinogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Acetylcholine in mind: a neurotransmitter correlate of consciousness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Levodopa-induced psychosis: a kindling phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Neuropsychological and perceptual defects in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Reality monitoring and visual hallucinations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Visual hallucinations induced by deep brain stimulation in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

The emerging role of clozapine in the treatment of movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Rationale for current therapies in Parkinson’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Treatment of psychosis in Parkinson's disease: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Clozapine-responsive tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Risperidone and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Atypical antipsychotics in Parkinson-sensitive populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Developments in the drug treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Severe worsening of parkinsonism in Lewy body dementia due to donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

Evaluating a hearing voices group for older people: preliminary findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0891988704267457

21 January 2018

Identifiers

DOI

10.1177/0891988704267457

1 reference

release_v6djnf5yrbamvi2hcsdsisgyre

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v6djnf5yrbamvi2hcsdsisgyre

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference